Author:
Bellido Virginia,Martínez Julia,Calvo Fernando,Villarroel Aida,Lecumberri Edurne,Moreno Juan,Morillas Carlos,Rodrigo Silvia,Izarra Aitziber,Lecube Albert
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference75 articles.
1. Dhillon S. Dapagliflozin: a review in type 2 diabetes. Drugs. 2019;79:1135–46. https://doi.org/10.1007/s40265-019-01148-3.
2. Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14:83–90. https://doi.org/10.1111/j.1463-1326.2011.01517.x.
3. Centro de información online de medicamentos de la AEMPS (CIMA). Ficha técnica Forxiga [Internet]. Accessed 11 Jun 2021. Available at: https://cima.aemps.es/cima/dochtml/ft/112795007/FT_112795007.html
4. Leoncini G, Russo E, Bussalino E, Barnini C, Viazzi F, Pontremoli R. SGLT2is and renal protection: from biological mechanisms to real-world clinical benefits. IJMS. 2021;22:4441. https://doi.org/10.3390/ijms22094441.
5. Wang D, Luo Y, Wang X, Orlicky DJ, Myakala K, Yang P, et al. The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents renal and liver disease in Western diet induced obesity mice. Int J Mol Sci. 2018;19(1):137. https://doi.org/10.3390/ijms19010137.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献